ROCKET: A randomized, multicenter phase 2 study of RRx-001+irinotecan versus regorafenib in 3rd/4th line colorectal cancer. Reid, T. R., Fisher, G. A. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.3526

View details for Web of Science ID 000487345805104